HC Wainwright Issues Positive Outlook for OKUR Earnings

OnKure Therapeutics, Inc. (NASDAQ:OKUR) – HC Wainwright increased their Q2 2026 earnings per share estimates for OnKure Therapeutics in a research note issued on Monday, July 20th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.39) per share for the quarter, up from their prior estimate of ($0.93). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for OnKure Therapeutics’ Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.94) EPS.

A number of other brokerages also recently weighed in on OKUR. Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. JonesTrading cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, OnKure Therapeutics has an average rating of “Hold” and a consensus price target of $21.00.

OnKure Therapeutics Trading Down 2.3%

Shares of NASDAQ OKUR opened at $4.22 on Wednesday. OnKure Therapeutics has a one year low of $1.91 and a one year high of $5.38. The business has a 50-day moving average price of $4.21 and a two-hundred day moving average price of $3.76. The firm has a market capitalization of $170.49 million, a PE ratio of -0.97 and a beta of 0.27.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.37).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of OKUR. DV Trading LLC purchased a new stake in shares of OnKure Therapeutics during the 1st quarter worth about $998,000. NewEdge Advisors LLC acquired a new stake in shares of OnKure Therapeutics during the 1st quarter valued at about $184,000. Vivo Capital LLC bought a new stake in shares of OnKure Therapeutics in the 1st quarter valued at approximately $7,981,000. ADAR1 Capital Management LLC increased its holdings in OnKure Therapeutics by 140.1% in the first quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock worth $10,081,000 after buying an additional 1,420,783 shares during the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in OnKure Therapeutics in the first quarter worth approximately $998,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.